Correlation between serum laminin levels and prognosis of acute myocardial infarction

Abstract

BackgroundAcute myocardial infarction (AMI) is a critical cardiovascular disease (CVD). Laminin (LN) is involved in the process of myocardial fibrosis and ventricular remodeling observed in AMI; however, there are currently no studies on the correlation between LN and AMI prognosis.PurposeTo explore the predictive value of serum LN levels for major adverse cardiovascular events (MACE) in patients, 6 months after an acute myocardial infarction.MethodsA total of 202 AMI patients who were hospitalized in the Department of Cardiology of the Second Affiliated Hospital of Nantong University between December 2019 and December 2020 were included. The observation endpoint was the occurrence of MACE. Univariate and multivariate logistic analyses were used to evaluate the relationships between the variables and endpoint. The predictive value of LN for MACE in AMI patients was assessed using receiver operating characteristic (ROC) analysis.ResultsA total of 47 patients developed MACE. Univariate logistic analysis showed that smoking, emergency percutaneous coronary intervention (EPCI), age, cardiac troponin I (c-TNI) levels, N-terminal prohormone brain natriuretic peptide (NT-proBNP) levels, and LN levels were associated with the occurrence of MACE (p < 0.05). Multivariate logistic analysis showed that LN was an independent predictor of MACE (odds ratio [OR] = 1.021, 95%CI: 1.014–1.032, p < 0.001). According to the ROC curve, LN can be used as an effective predictor of MACE (AUC = 0.856, 95%CI: 0.794–0.918, p < 0.001). According to the cutoff value, LN>58.80 ng/ml (sensitivity = 83.00%, specificity = 76.80%) or LN>74.15 ng/ml (sensitivity = 76.6%, specificity = 83.2%) indicate a poor prognosis for AMI. Different cut-off values are selected according to the need for higher sensitivity or specificity in clinical applications.ConclusionsLN may be a predictor of MACE following AMI in patients and could be utilized as a novel substitute marker for the prevention and treatment of AMI.

The Current State of Extracellular Matrix Therapy for Ischemic Heart Disease

“…In rats following myocardial infarction, laminin deposition was noted, with a distribution that started at the periphery of the infarct border within granulation tissue, and gradually extended to the outer lesion of the central infarct zone, suggesting that LNs are implicated in the repair process [72]. Furthermore, higher LN levels may correlate with prognosis following acute MI as seen with one study which demonstrated a higher degree of major adverse cardiac events in patients with higher LN levels [73]. As such, the modulation of LN may represent an opportunity for treatment.…”

Correlations between serum laminin level and severity of heart failure in patients with chronic heart failure

“…Laminin (LN) is a vital component of ECM, which has significant biological functions, including adhesion, translocation, cell differentiation, cell growth, and inflammatory response ( 4 ). Many studies have shown that LN is closely related to the process of myocardial fibrosis ( 5 – 7 ). The 2022 AHA/ACC/HFSA guidelines ( 8 ) divide HF into four stages (stages A–D) according to HF progression, which objectively reflects the clinical progress of CHF.…”